J Hematol

Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc

Journal website http://www.thejh.org

Original Article

Volume 8, Number 2, June 2019, pages 47-54

Plasma Factors for the Differentiation of Hodgkin’s Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission

Figure 1. Soluble CD30 (sCD30) and CCL22 have diagnostic potential for HL patients. Medians with interquartile ranges of (a) sCD30, (b) CCL22 and (c) CXCL13 plasma levels in healthy donors, new cases of HL patients and DLBCL patients are shown. *P < 0.05, **P < 0.01, ****P < 0.0001 (Mann-Whitney U test).

Figure 2. Screening of soluble factors for the confirmation of remission status of cHL. Plasma of different cHL patients at diagnosis (new cases (NC)) were compared with plasma of healthy controls (HC) and plasma of cHL patients in remission (Rem). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Mann-Whitney test).

Figure 3. Verification of soluble factors for the confirmation of remission status of cHL. Eight pairs of cHL patient plasma before treatment (new case (NC)) and after remission (Rem) were measured for TNFR2 level. *P < 0.05 (two-tailed, Wilcoxon matched-pairs signed rank test).

Figure 4. Soluble factors for the confirmation of remission status of DLBCL. Eight pairs of DLBCL patient plasmas before treatment (new cases (NC)) and after remission (Rem) were analyzed for (a) IL-2, (b) sIL-2R, and (c) IL-31 concentrations. *P < 0.05, **P < 0.01 (two-tailed, Wilcoxon matched-pairs signed rank test).

**Table 1.** Statistics of the Patients
	Cases	Age/median (interquartile range)
^aNumbers in parenthesis indicate the percentage of patients who eventually achieved remission. ^bSeven cases are from patients already included in the screening test for initial diagnosis.
Screening test
cHL	13 (61.5%)	14	26	49 (73.5%)	27 (22.25, 33.25)	28 (23, 38.5)
DLBCL	22 (59.1%)	0	-	22 (59.1%)	61 (50.75, 72.75)	61 (50.75, 72.75)
Healthy controls	-	-	-	12		27 (25, 29.75)
Verification test
cHL	8^b		8	8	-	-
DLBCL	8		8	8	-	-

Table 1. Statistics of the Patients

Cases

Age/median (interquartile range)

At initial diagnosis (remission %)^a

During treatment or relapse

In remission

Total (remission %)^a

At initial diagnosis

Total

^aNumbers in parenthesis indicate the percentage of patients who eventually achieved remission. ^bSeven cases are from patients already included in the screening test for initial diagnosis.

Screening test

cHL

13 (61.5%)

49 (73.5%)

27 (22.25, 33.25)

28 (23, 38.5)

DLBCL

22 (59.1%)

61 (50.75, 72.75)

Healthy controls

27 (25, 29.75)

Verification test

cHL

8^b

DLBCL

**Table 2.** Soluble Factors That Occur at Concentrations Significantly Different Between the Plasma of Initially Diagnosed cHL Patients and Healthy Controls
	Healthy control	HL initial diagnosis	DLBCL initial diagnosis	P (cHL vs. healthy)	P (cHL vs. DLBCL)
Listed are the median values of respective concentrations (pg/mL). ^aThe three soluble factors that are both significantly different in cHL vs. healthy control, and in cHL vs. DLBCL. P values were calculated using Mann-Whitney U test. ND: not detectable.
sCD137L	8.59	55.70	46.09	0.00591	0.724
sCD137	53.06	64.38	159.30	0.54963	0.009
sBAFF	ND	31.58	4.55	0.00278	0.159
CXCL13^a	81.19	279.84	152.41	0.00009	0.041
sCD30^a	141.79	885.04	369.44	0.00002	0.015
ENA78	ND	142.28	270.10	0.00005	0.555
Eotaxin	11.80	30.33	25.13	0.00110	0.428
Eotaxin-2	43.39	94.38	63.22	0.03164	0.169
FGF-2	ND	11.47	ND	0.00828	0.408
HGF	11.85	110.24	140.76	0.00007	0.302
IFN-γ	ND	55.79	54.08	0.00002	0.88
IL-15	ND	7.79	4.81	0.00673	0.319
IL-16	562.79	262.40	463.37	0.01233	0.041
IL-18	ND	77.19	102.40	0.00019	0.933
IL-2R	1,982.09	9,679.94	10,279.12	0.00331	0.533
IL-20	ND	4.60	0.57	0.01427	0.062
IL-23	ND	22.07	ND	0.03562	0.408
IL-3	ND	33.25	15.01	0.00126	0.302
IL-31	ND	102.72	41.64	0.00828	0.489
IL-4	ND	26.52	3.93	0.01406	0.287
IL-7	ND	1.04	1.17	0.00039	0.88
IL-8	ND	1.01	ND	0.03557	0.625
IL-9	ND	4.69	0.96	0.01762	0.987
IP-10	5.10	47.39	39.94	0.00007	0.428
CCL8	1.05	10.24	9.15	0.00009	0.353
CCL22^a	67.01	619.59	128.30	0.00361	0.013
MIP-1 α	ND	7.05	3.27	0.02283	0.169
MIP-3 α	ND	17.44	17.44	0.00828	0.462
SDF-1 α	465.55	ND	ND	0.00026	0.801
TSLP	ND	17.03	12.61	0.00451	0.169
VEGF-A	ND	35.21	15.07	0.00126	0.257

Table 2. Soluble Factors That Occur at Concentrations Significantly Different Between the Plasma of Initially Diagnosed cHL Patients and Healthy Controls

Healthy control

HL initial diagnosis

DLBCL initial diagnosis

P (cHL vs. healthy)

P (cHL vs. DLBCL)

Listed are the median values of respective concentrations (pg/mL). ^aThe three soluble factors that are both significantly different in cHL vs. healthy control, and in cHL vs. DLBCL. P values were calculated using Mann-Whitney U test. ND: not detectable.

sCD137L

8.59

55.70

46.09

0.00591

0.724

sCD137

53.06

64.38

159.30

0.54963

0.009

sBAFF

31.58

4.55

0.00278

0.159

CXCL13^a

81.19

279.84

152.41

0.00009

0.041

sCD30^a

141.79

885.04

369.44

0.00002

0.015

ENA78

142.28

270.10

0.00005

0.555

Eotaxin

11.80

30.33

25.13

0.00110

0.428

Eotaxin-2

43.39

94.38

63.22

0.03164

0.169

FGF-2

11.47

0.00828

0.408

HGF

11.85

110.24

140.76

0.00007

0.302

IFN-γ

55.79

54.08

0.00002

0.88

IL-15

7.79

4.81

0.00673

0.319

IL-16

562.79

262.40

463.37

0.01233

0.041

IL-18

77.19

102.40

0.00019

0.933

IL-2R

1,982.09

9,679.94

10,279.12

0.00331

0.533

IL-20

4.60

0.57

0.01427

0.062

IL-23

22.07

0.03562

0.408

IL-3

33.25

15.01

0.00126

0.302

IL-31

102.72

41.64

0.00828

0.489

IL-4

26.52

3.93

0.01406

0.287

IL-7

1.04

1.17

0.00039

0.88

IL-8

1.01

0.03557

0.625

IL-9

4.69

0.96

0.01762

0.987

IP-10

5.10

47.39

39.94

0.00007

0.428

CCL8

1.05

10.24

9.15

0.00009

0.353

CCL22^a

67.01

619.59

128.30

0.00361

0.013

MIP-1 α

7.05

3.27

0.02283

0.169

MIP-3 α

17.44

0.00828

0.462

SDF-1 α

465.55

0.00026

0.801

TSLP

17.03

12.61

0.00451

0.169

VEGF-A

35.21

15.07

0.00126

0.257